Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance

Abstract

Paraoxonase-1 (PON1) is a high-density lipoprotein-associated esterase and is speculated to play a role in several human diseases including diabetes mellitus and atherosclerosis. Low PON1 activity has been associated with increased risk of major cardiovascular events, therefore a variety of studies have been conducted to establish the cardioprotective properties and clinical relevance of PON1. The major aim of this review was to highlight the important studies and to subsequently assess if PON1 has clinical relevance. A review of the literature showed that there is currently insufficient data to suggest that PON1 has clinical relevance. It is our opinion that robust studies are required to clarify the clinical relevance of PON1.

Keywords:

• antioxidant
• inflammation
• atherosclerosis
• cardiovascular disease

Disclosure

PN is employed by Sanofi and NS is a previous employee of Sanofi. Sanofi has molecules in the lipid, antiplatelet, hypertension, diabetes, anticancer, anti-infective and antidepressant therapeutic areas. Neither PN nor NS own stocks in Sanofi. The other author reports no conflicts of interest in this work.